Serum levels of substance P are decreased in patients with type 1 diabetes

Summary:

Morphological and immunohistochemical studies in diabetic subjects have shown a depletion of the neuropeptide substance P (SP) in the central and peripheral nervous system. This is the first study investigating serum levels of substance P in type 1 diabetes patients (n = 50) and controls (n = 75) by means of an enzyme immunoassay. The serum level of SP was significantly decreased in the diabetic group compared to the control group (10.12 ± 0.29 vs. 12.25 ± 0.38 pg/ml; p < 0.0001). In diabetic patients, there was no correlation of substance P levels with age, serum creatinine, albuminuria, total cholesterol, HDL- or LDL-cholesterol, triglycerides, HbA1c, type or duration of diabetes and gender. Furthermore, there was no difference in serum levels of SP in patients with or without retinopathy, but SP was significantly decreased in patients with neuropathy (9.59 ± 0.48 vs. 10.78 ± 0.83 pg/ml; p = 0.04).

These data show that SP is decreased in serum of type 1 diabetes patients, especially in those with diabetic neuropathy. Subsequent and already ongoing prospective studies in well validated diabetic patients with neuropathy may characterize the impact of this neurogenic marker in the course of diabetic neuropathy.

Abbreviations: SP = substance P; EIA = enzyme immunoassay; HDL = high density lipoprotein; LDL = low density lipoprotein

Substance P - diabetes mellitus - serum level - neuropathy

References

• 1 Bloom S R, Polak J M, Laybourn P J, Najarian R C. Regulatory peptides and the skin.  Clin Exp Dermatol. 8 3-18 1983; 
• 2 Blumberg A, Bürgi W. Behaviour of β₂-microglobulin in patients with chronic renal failure undergoing hemodialysis, hemodiafiltration and continuous ambulatory peritoneal dialysis (CAPD).  Clin Nephrol. 27 245-249 1987; 
• 3 Boden G, Master R W, Owen O E, Rudnick M R. Human pancreatic polypeptide in chronic renal failure and cirrhosis of the liver: role of kidneys and liver in pancreatic polypeptide metabolism.  J Clin Endocrinol Metab. 51 573-578 1980; 
• 4 Chang M M, Leeman S E, Nrall H D. Amino acid sequence of substance P.  Nature. 232 86-87 1971; 
• 5 Church M K, Lowman M A, Robinson C, Holgate S T, Benyon R C. Interaction of neuropeptides with human mast cells.  Int Arch Allergy Appl Immunol. 88 70-78 1989; 
• 6 Conlon J M, Deacon C F, Richter G, Stcökmann F, Creutzfeldt W. Circulating tachykinins (substance P, neurokinin A, neuropeptide K) and the carcinoid flush.  Scand J Gastroenterol. 22 97-105 1987; 
• 7 Dalsgaard C J, Johnsson C E, Hökfelt T, Cuello A C. Localization of substance P-immunoreactive nerve fibers in the human digital skin.  Experientia. 39 1018-1020 1983; 
• 8 Davidson W D, Springberg P D, Falkinburg N R. Renal extraction and excretion of endogenous gastrin in dog.  Gastroenterology. 64 955-961 1973; 
• 9 Eedy D J. Neuropeptides in skin.  Br J Dermatol. 128 597-605 1993; 
• 10 Hegbrant J, Thysell H, Ekman R. Plasma levels of vasoactive regulatory peptides in patients receiving regular hemodialysis treatment.  Scand J Urol Nephrol. 26 169-176 1992; 
• 11 Kastrup J, Henriksen J H, Pedersen J H, Fahrenkrug J, Schaffalitzky de Muckadell O B, Schwartz T, Parving H H, Christensen N J. Effect of ganglionic blockade on endogenous circulating pancreatic polypeptide, vasoactive intestinal polypeptide. substance P, neurotensin and noradrenaline in healthy controls and long-term insulin-dependent diabetic patients.  Clin Sci. 71 411-419 1986; 
• 12 Katz A I, Rubenstein A H. Metabolism of proinsulin, insulin and c-peptide in the rat.  J Clin Invest. 52 1113-1121 1973; 
• 13 Levy D M, Karanth S S, Springall D R, Polak J M. Depletion of cutaneous nerves and neuropeptides in diabetes mellitus: an immunocytochemical study.  Diabetologia. 32 427-433 1989; 
• 14 Lindberger M, Schroder H D, Schultzberg M, Kristensson K, Persson A, Ostman J, Link H. Nerve fiber studies in skin biosies in peripheral neuropathies. I. Immunohistichemical analysis of neuropeptides in diabetes mellitus.  J Neurol Sci. 93 289-296 1989; 
• 15 Lysy J, Karmeli F, Goldin E. Substance P levels in the rectal mucosa of diabteic patients with normal bowel function and constipation.  Scand J Gastroenterol. 28 49-52 1993; 
• 16 Marshall K W, Chiu B, Inman R D. Substance P and arthritis: analysis of plasma and synovial fluid levels.  Arthritis Rheum. 33 87-90 1990; 
• 17 Mori K, Asakura S, Morokawa N, Takeyama M. Effect of terfenadine on the plasma concentrations of substance P and vasoactive intestinal polypeptide in volunteers.  J Pharm Pharmacol. 44 856-858 1992; 
• 18 Said S I. Vasoactive peptides. State-of-the-art review.  Hypertension 5 (Suppl 1) I17-26 1983; 
• 19 Saria A. Neuropeptide.  Hautarzt. 43 745-752 1992; 
• 20 Schaffalitzky de Muckadell O B, Aggestrup A, Stentoft P. Flushing and substance P concentration during infusion of synthetic substance P in normal man.  Scand J Gastroenterol. 21 498-502 1986; 
• 21 Schmidt R E, Dorsey D A, Roth K A. Immunohistochemical characterization of NPY and substance P containing nerve terminals in aged and diabetic human sympathic ganglia.  Brain Res. 583 320-326 1992; 
• 22 Snyder S H. Brain peptides as neurotransmitters.  Science. 209 976-983 1980; 
• 23 Tanio H, Vaalasti A, Rechardt L. The distribution of substance P-, CGRP-, galanin- and ANP-like immunoreactive nerves in human sweat glands.  Histochem J. 19 375-380 1987; 
• 24 Thysell H, Grubb A, Lindholm T, Ljunggren L, Martenson L. Cystatin C: a new marker of biocompatibility or a good marker for the redistribution of LMW proteins during hemodialysis?.  Trans Am Soc Artif Intern Organs. 34 202-204 1988; 
• 25 Valdemarsson S, Edvinsson L, Ekman R, Hedner P, Sjöholm A. Increased level of substance P in patients with severe congestive heart failure treated with ACE inhibitors.  J Int Med. 230 325-331 1991; 
• 26 Von Euler V S, Gaddum J H. An unidentified depressor substance in certain tissue extracts.  J Physiol (London). 72 74-87 1931;